Dermata Therapeutics, Inc. (DRMAW) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
애널리스트 추정 주당순이익(EPS) $-147.80 및 매출 $0.00B 다음 회계연도.
주당순이익(EPS) 실적 추이: 2024: 실적 $-8,032.22 vs 추정 $-147.80 (하회 -5334.5%). 2025: 실적 $-8.16 vs 추정 $-8.00 (하회 -2%). 애널리스트 정확도: 50%.
